The results provided clearly suggested that targeting STAMBP to inhibit E2F1-PDK1 axis-mediated glycolysis may be a new strategy for overcoming malignant progression and GEM resistance in PC. This evidence concerns the gene STAMBP and pachyonychia congenita.